Oct 11, 2022

PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial

Sep 19, 2022

PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted

Sep 7, 2022

PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022

Aug 29, 2022

PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

Aug 11, 2022

PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application

Aug 8, 2022

PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent Applications

Jun 27, 2022

PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of Shareholders

Jun 2, 2022

PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds

May 30, 2022

PsyBio Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones

May 16, 2022

PsyBio Therapeutics Develops Commercial Purification Process for Second Generation Psycho-Targeted Compound

May 6, 2022

PsyBio Therapeutics Initiates Blood-Brain Barrier Permeability Testing for Pipeline Compounds to Enhance Portfolio Development

Apr 29, 2022

KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing